direct-acting antiviral

December 13, 2016December 13, 2016

Gilead Submits New Drug Application for Once-daily Single Tablet Regimen for HCV

Hepatitis C, News

Gilead Sciences submitted a regulatory new drug application (NDA) for its investigational, once-daily single tablet regimen of SOF/VEL/VOX (sofosbuvir, velpatasvir, and voxilaprevir) for the treatment of hepatitis C infection with the ... Read more

December 6, 2016December 6, 2016

European Medical Officials Join Chorus of Warnings About Risk of Hep B Reactivation with Direct-Acting Antiviral Drugs Used for Hep C

Hepatitis B, Hepatitis C, News

The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has confirmed that patients being treated with certain direct-acting antiviral (DAA) drugs for hepatitis C virus (HCV) infection ... Read more

October 6, 2016October 6, 2016

FDA Warns Risk of Hepatitis B Reactivating with Certain Antiviral Drugs for Hepatitis C

Hepatitis B, Hepatitis C, News

Earlier this week, the U.S. Food and Drug Administration (FDA) warned about serious risks for patients infected with the hepatitis B virus (HBV) and who are being treated with certain direct-acting antiviral ... Read more

March 24, 2016March 24, 2016

Tailored Approach to Hepatitis C Cure Is More Cost-Effective, According to Study

Hepatitis C, News

Researchers at Loyola University Health System and Loyola University Chicago have determined that costs for hepatitis C virus (HCV) treatment could be cut up to 50 percent if mathematical models are used to ... Read more

September 1, 2015September 1, 2015

One in Four Chronic Hepatitis C Patients Are Denied Initial Approval for Drug Therapy

News

Results from a recent study entitled “Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade“, published in the journal ... Read more